The Continuous Glucose Monitoring (CGM) market is projected to reach $31.41 billion by 2031, growing at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031. Key drivers of market growth include the rising prevalence of diabetes, the sedentary lifestyle of a growing population, the advantages of CGM over traditional glucose monitoring methods, and the adoption of CGM by athletes and fitness enthusiasts. Additionally, technological advancements, personalized care trends, and increased accessibility to diabetes care devices in low and middle-income countries present significant opportunities for market expansion. Download free sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5960 Key Market Drivers Increasing Prevalence of Diabetes CGMs provide real-time glucose level readings, enhancing diabetes management by allowing continuous monitoring and timely alerts. For example, the FDA approved the Dexcom Stelo Glucose Biosensor System in March 2024, an OTC integrated CGM suitable for patients over 18 not requiring insulin and without severe hypoglycemia. Risk factors like obesity, poor diet, sedentary lifestyle, and genetic predisposition continue to drive the demand for effective glucose monitoring solutions. According to WHO, around 422 million people globally have diabetes, underscoring the need for continuous glucose monitoring. Advantages of CGM Over Conventional Monitoring CGM devices offer real-time data monitoring, trend analysis, alerts for high or low glucose levels, and reduced reliance on fingerstick tests. The integration of AI in CGM devices enhances diabetes management. For instance, January, Inc. launched an AI-supported app in May 2023 that predicts glucose patterns and provides recommendations on diet and activity, demonstrating the increasing role of AI in healthcare. Emerging Trends Integration of Smart Devices and AI Smart CGM devices predict glucose level fluctuations and offer advanced algorithms for better glucose management. The Guardian Connect CGM System by Medtronic allows users to track glucose patterns every five minutes. AI integration in these devices helps in predicting sugar levels and creating personalized diabetes management plans. For example, Roche's AI-powered Accu-Chek SmartGuide system launched in March 2024 predicts glucose fluctuations, facilitating better diabetes management. Browse in depth: https://www.meticulousresearch.com/product/continuous-glucose-monitoring-market-5960 Rising Adoption of Wearable Devices The COVID-19 pandemic has accelerated the adoption of wearable healthcare technology. Wearable CGM devices provide real-time monitoring, reducing the need for frequent clinic visits. The emphasis on preventive healthcare and personalized medicine is driving the adoption of CGM devices. Market Opportunities Technological Advancements Technological innovations in CGM devices, such as wireless connectivity, enzyme-based electrochemical sensors, and integration with insulin pumps, are enhancing their accuracy and reliability. For example, Senseonics Holdings' Eversense® E3, approved by the FDA in February 2022, is an implantable CGM that can remain in the body for six months. Market Segmentation and Analysis By Component In 2024, sensors are expected to dominate the CGM market, accounting for over 52.4% of the market share. The frequent replacement of sensors compared to transmitters and receivers drives this segment's growth. By Age Group The adult segment is projected to hold a larger market share due to the high prevalence of diabetes among the geriatric population and the sedentary lifestyle leading to obesity. However, the children's segment is anticipated to register the highest growth rate, driven by the increasing diagnosis of type 1 diabetes in this age group. Download request sample report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5960 By End User Home care settings are expected to dominate the market in 2024, accounting for over 82.3% of the market share. Factors such as the rising prevalence of diabetes, increasing health awareness, and the shift towards preventive healthcare support this trend. Geographical Insights North America North America is expected to lead the CGM market in 2024, accounting for over 42.2% of the market share. The region's advanced technological infrastructure, significant R&D investments, and supportive government initiatives contribute to this dominance. Asia-Pacific The Asia-Pacific region is projected to register the highest CAGR of over 17.40% during the forecast period, driven by improving healthcare infrastructure, rising disposable income, and increased investments by major market players. Quick buy: https://www.meticulousresearch.com/Checkout/64947495 Key Companies and Recent Developments Leading Players Key players in the CGM market include DexCom, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic PLC, Nemaura Medical Inc., LifeScan, Inc., Senseonics Holdings, Inc., A. Menarini Diagnostics S.r.l, Medtrum Technologies, Inc., and B. Braun SE. Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
